Novel molecular diagnostic tests like the combination of HOMA, AST, and CK18 (MACK-3) have been extensively evaluated and offer promising avenues for identifying high-risk NASH patients, while simpler scores such as Fibrotic NASH Index (FNI) show good performance for ruling out fibrotic NASH [91, 92]. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatohepatitis.